IPCA Laboratories fell 2.21% to Rs 1563 after consolidated net profit fell 14% to Rs 83.05 crore on 22% rise in total income to Rs 1087.49 crore in Q4 March 2020 over Q4 March 2019.
Profit before tax (PBT) stood at Rs 112.25 in Q4 FY20, down by 12.1% from Rs 127.67 crore in Q4 FY19. Tax expense fell 8% to Rs 29.20 in Q4 March 2020 over Q4 March 2019.
The company recorded a forex loss of Rs 23.62 in Q4 FY20 as against forex gain of Rs 4 lakh in Q4 FY19. Finance costs fell 43% year-on-year (YoY) to Rs 3.67 during the quarter.
Depreciation and amortisation costs surged 43% YoY to Rs 63.94 in the fourth quarter. The company provided for impairment of intangible assets to the tune of Rs 27.64 crore during the quarter.
Total formulations revenue jumped 17% to Rs 713.43 crore during the quarter. Revenue from domestic fomulations business rose 21% to Rs 430.96 crore in Q4 FY20 over Q4 FY19.
Total APIs revenue rose 30% to Rs 275.07 crore in Q4 FY20 over Q4 FY19. Revenue from domestic APIs (up 41%) and APIs exports (up 27%).
Consolidated net profit rose 36% to Rs 603.56 crore on 23% increase in total income to Rs 4,715.71 crore in the year ended March 2020 (FY20) over the year ended March 2019 (FY19). PBT stood at Rs 738.89 crore in FY20, up by 35.21% from Rs 546.46 crore in FY19.
IPCA Laboratories is a vertically integrated pharmaceutical company. It produces finished dosage forms and active pharmaceutical ingredients.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app